ProMetic Life Sciences Inc. (TSE:PLI – Get Free Report) shares were up 0.2% on Monday . The company traded as high as C$13.72 and last traded at C$13.60. Approximately 921 shares were traded during trading, a decline of 88% from the average daily volume of 8,002 shares. The stock had previously closed at C$13.57.
ProMetic Life Sciences Stock Performance
The company has a quick ratio of 3.66, a current ratio of 4.06 and a debt-to-equity ratio of 37.47. The firm has a market capitalization of C$317.06 million and a PE ratio of -0.22. The business has a fifty day moving average of C$13.60.
ProMetic Life Sciences Company Profile
Prometic Life Sciences Inc operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals.
Featured Articles
- Five stocks we like better than ProMetic Life Sciences
- 3 Tickers Leading a Meme Stock Revival
- How Much Can You Make in Stocks in One Month?
- What Investors Need to Know About Upcoming IPOs
- This Is the Top Large-Cap Stock Insiders Are Buying
- How to Invest in the Best Canadian Stocks
- Capitalize on Micron’s 24% Drop—Wall Street Eyes Major Upside
Receive News & Ratings for ProMetic Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
